A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Bringing a game of this magnitude from the home of Connacht Rugby in the Dexcom Stadium in Galway is not only huge for the ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...